藥物化學加值創新研發中心
Value-Added MedChem Innovation Center

Tel:	+886-37-206-166 # 35742
Website:	http://ibpr.nhri.org.tw/zhtw/index.php/vmic/
Room No.	C802, C803, C817, C818
Business/ Company Profile	國衛院生技藥研所為發揮既有技術能量，配合政府推動「亞太生技醫藥研發產業中心」政策，參與由中研院推動之「生技醫學轉譯創新發展計畫-技術支援平台主軸, TSPA」，2017年設立藥物化學加值創新研發中心，從活性化合物至先導化合物最適化及先導化合物至候選發展藥物最適化等研發工作，透過以客戶需求為導向之藥物化學加值工作，提高候選發展藥物產出效率與品質，促進廠商轉型投入高附加價值的新穎藥物研發領域，帶動生技產業升級。 IBPR starts up a new platform called Value-Added MedChem Innovation Center (VMIC) from 2017 to leverage integrated medicinal chemistry research with well-established drug research platform technologies to support the small molecule drug discovery projects for the companies, academic/research institutes. VMIC’ s mission is to provide customer-driven service or collaboration in medicinal chemistry for hit-to-lead and lead-to-candidate. IBPR also exerts its systematic research mechanism and experiences in drug discovery and development stages to bridge the long-existing gap between academia research and industrialization. VMIC’ s goal is to enable local pharmaceutical and biotech companies to engage in innovative drug discovery and to upgrade the entirety of the biotechnology and pharmaceutical industry in Taiwan.

Immunwork

免疫功坊股份有限公司
Immunwork Inc.

Tel:	+886-965-026589
Website:	http://www.immunwork.com
Room No.	C521
Business/ Company Profile	免疫功坊於2014年10月由張子文博士成立，是一個以研發為主的新藥公司，利用擁有多項自行開發專利的「T-E®型藥物新藥設計平台」，能用模組化的方式針對不同的疾病領域設計出一系列的新藥「T-E®型藥物」。此類藥物分子可同時具有多種功能，主要涵蓋兩種功能部位：標的部位與效應部位。依據不同的適應症，可以選擇不同的標的元件或是效應元件，以模組化的設計方式產生各式不同的新藥。此技術可廣泛使用於抗體藥物複合物，抗體放射性核種複合物，及雙特異性抗體等領域藥物的發展。目前用以治療癌症（TE-1122、TE-1422）、病理性血栓（TE-6168）、及糖尿病（TE-8104）的準藥物，已準備進入臨床前期的試驗。 Immunwork, Inc. was founded in October 2014. We focus on the research, development, and commercialization of a series of new drugs, which have been created based on our proprietary technology platform, to treat multiple types of cancer, diabetes, pathological clots, and other selected severe diseases. Our technology platform enables us to design a class of new pharmaceuticals, which we term “T-ETM pharmaceuticals”. These new pharmaceuticals contain two functional moieties: a targeting (T) moiety and an effector (E) moiety. The drug-design platform can be employed for constructing antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), bispecific antibodies, and other pharmaceutical configurations. Four lead candidates have been identified, including TE-1122 and TE-1422 for treating oncology, TE-6168 for treating pathological clots, and TE-8104 for treating diabetes. These lead candidates are planned to enter preclinical deveopment.

欣耀生醫股份有限公司
SINEW PHARMA INC.

Tel:	+886-2-2655-7269 #5113
Website:	https://www.sinewpharma.com
Room No.	C516, C517
Business/ Company Profile	欣耀生醫是以發明新藥來解決目前世界上尚未解決而亟待解決的重大疾病，如：1. 脂肪肝炎造成的肝硬化、肝癌；2. 藥物造成的嚴重肝損傷；其中乙醯胺酚(Acetaminophen)是全球導致急性肝衰竭的主因。欣耀核心產品有6項，2項是「治療脂肪肝炎疾病用新藥」，其餘4項是全球首例無肝毒性止痛新藥、解毒劑。核心技術是人體代謝酵素活性及酵素基因調控平台。團隊成員有235人-年研發經驗，更有完整從頭研發至成功上市之經驗（世界首例新長效七日無成癮性止"劇"痛葯）。 Sinew Pharma is a new drug development company that invents new drugs to solve the problem of urgent unmet medical needs that are currently unresolved in the world, including (1) cirrhosis and hepatoma caused by non-alcoholic steatohepatitis (NASH); (2) severe liver damage caused by drugs, among which Acetaminophen is the leading cause of acute liver failure worldwide. There are six core products under development. Two are “new drugs for the treatment of and prevention of NASH". The other four are “the world's first new hepatotoxicity-free acetaminophen and antidote". The core technology is the "human metabolic enzyme activity and enzyme gene" modulation platform. The team members have 235 people-years of R & D experience, and complete experience from de novo development to successful listing (world first new 7-day long-acting, non-addictive opioid for severe pain control).

矽基分子電測科技股份有限公司
Silicon Based Molecular Sensoring Technology CO., LTD.

Tel:	+886-2-2783-5173
Website:	http://www.molsentech.com
Room No.	C416
Business/ Company Profile	矽基分子電測成立於2014年，致力發展可即時檢測極微量致病性病原體的「矽場效應電晶體微量生醫分子即時檢測儀」以及「高靈敏度疾病體外檢測生醫晶片」。核心團隊來自中央研究院物理所量子電子元件實驗室，充分掌握半導體晶片設計製作、生化探針分子表面修飾與整合自動化生物檢測器系統等核心技術，曾獲得國際SCI一級期刊的肯定及多項獎項。本公司秉持創新、服務、高品質的理念，將提供全球檢測市場高靈敏度、高準確度以及簡易操作的新興產品。 Founded in 2014, Molsentech is dedicated to developing a biomedical platform that facilitates the non-invasive and real-time detection of minimum pathogens for patients. Our core team is composed of professionals from the Quantum Electronic Laboratory at Academia Sinica with exclusive expertise in semiconductor chip design/fabrication, probe molecules modification and automation bio-sensor system integration. In addition, our researches were published by SCI journal and earned relevant patents. With widely-recognized performance, Molsentech was honored to win the 13th National Innovation Award in 2016. Going forward, Molsentech will leverage this top-notch platform to provide high sensitive, accurate and user-friendly products in the biomedical detection market worldwide.

昱星生物科技股份有限公司
LumiSTAR Biotechnology, Inc.

Tel:	+886-2-2783-5860
Website:	http://www.lumistar.com.tw
Room No.	C524
Business/ Company Profile	昱星生技聚焦於人類誘導式幹細胞 (iPSC) 模組之高效能藥物篩檢及毒性測試平台，以及更進一步將此平台技術提供做為個人化、精準化醫療服務之檢測技術。主要核心技術為生理蛋白指示劑之開發 (genetically encoded tools)，可用於細胞生理或特定胞器之長時間追蹤; 以及人類誘導式幹細胞 (iPSC) 相關技術之藥物篩檢應用；並結合光遺傳學工具的設計，提供藥廠及 CRO 公司做大規模的新藥開發及毒性測試。此平台技術另一方面可應用於高效能精準化、個人化醫療之服務，亦為公司發展之重點項目。 LumiSTAR Biotechnology is an expert in designs of a range of protein-based indicators for cellular dynamics measurements. Our expertise includes photochemistry, induced pluripotent stem cell (iPSC) technology, optogenetic tools and regenerative medicine. All of these technologies are packaged into a high content all-optical platform for phenotypic screening, drug discovery, and toxicity testing; the other application is for precision/personalized medicine. This high content platform enables customers to do their drug screening tasks in a more efficient and economical way. We offer a variety of functional assays or iPSC cell lines for different disease modelling; customization service is also available. Applications of Bio-imaging Platforms incorporated with iPSC Technology. (1) High Content Drug Discovery: Our platforms enable real-time monitoring cellular dynamics for high content screening. Protein-based reporters are non-toxic to the cells compared with traditional chemical dyes. Also, by incorporation with hiPSC, the whole platforms allow fast phenotypic screening for drug discovery/repurposing and toxicity test, effectively shorten the proof of concept cycle to hit the right target. (2) Precision/Personalized Medicine: LumiSTAR' s live reporters can be incorporated into customized organs on chips (derived from individual' s iPS cells) for direct signal read out. Direct drug testing can be done on your own cells, your own organs chips !

EXCELSIOR

Professionalism · Innovation · Excellence · Service

科懋生物科技股份有限公司 / 科進製藥科技股份有限公司
Excelsior Biopharma Inc. / Excelsior Pharmatech Labs.

Tel:	+886-972-821937
Website:	http://www.excelsiorgroup.com.tw/
Room No.	C621, C622
Business/ Company Profile	科懋集團長期致力於特殊疾病用藥開發和服務，子公司科進製藥於2016年於新竹生醫園區成立研究中心並投入乙型轉化生長因子新藥開發領域，開始篩選TGF-β 抑制劑或促進劑的相關候選藥物分子，並於2019進駐國家生技研究園區，結合國家生技研究園區資源，取得人才、技術、研發設備、資金、法規、及智財專利之完整規劃，期待藉由與產官學研等藥物開發相關單位的合作，進一步開發相關適應症的新藥，在建立台灣世界級的新藥研發中心。短期2~3年目標為開發出治療特定適應症的新藥專利，未來更放眼亞太特殊疾病臨床研究、精準醫學檢驗和新藥開發與供應。 Excelsior group has been dedicated to specialty medicines and medical supplies for more than two decades. In 2016, Excelsior Pharmatech Labs. established a TGF-β research center and start up new drug development projects from screening drug candidates targeting at TGF-β activities. Now in 2019, our TGF-β research center is expanding our team and moving into the incubation center of National Biotechnology Research Park, NBRP. In NBRP, we are expecting more connection with the intergraded supporting platform including human resource, technology, core facilities, funds, regulations, and intellectual property rights strategies from government, industry, and Academia Sinica. Our aim is to establish a world-class new drug development research center and transfer our research results into new drug patents in some specific indications in 2 to 3 years. In the future, we will also focus on the clinical research, new drug development and medical examination of specific diseases in Asian population.

mello biotech

美洛生物科技股份有限公司
Mello Biotech

Tel:	+886-2-2789-3558
Website:	http://www.mellobiotech.com
Room No.	C422
Business/ Company Profile	美洛生技為一個新藥研發公司，專注於微核糖核酸(microRNA) 及幹細胞方面核心技術。主要研發方向為運用 microRNA precursor 作癌症治療新藥。依據技術資料及市場可行分析，目前選定非小型肺腺癌為目標適應症。 目前已在動物原位生型肺癌模式試驗證明有效，並且在初步動物實驗證明新藥安全無副作用。基於這些成果，公司目標為將 microRNA 新藥帶入臨床，驗證在人體的有效性及安全性。具體短期工作目標包括安排製造試量產、毒理藥理實驗、IND及臨床一期。 Mello Biotech is a research company specializes in development and commercialization of microRNA and stem cell technologies. Based on patented proprietary technologies in microRNA and stem cells, Mello Biotech currently focuses on the development of microRNA precursor for cancer treatment. Based on technical and commercial viability, initial indication is targeting “4th stage NSCLC patients not eligible for target therapy or immunotherapy”. Current in-vivo study data demonstrates good efficacy and safety in orthotopic animal models. The company aims to validate efficacy and safety of treatment in human. Objectives include manufacturing, pre-clinical experiments, application for IND, and clinical trial phase I.

ALPS BIOTECH

浩峰生物科技股份有限公司
ALPS BIOTECH., LTD

Tel:	+886-2-2788-7626
Website:	http://www.alps.com.tw/
Room No.	C624
Business/ Company Profile	浩峰生技是一家以新藥開發為首要目標的生技公司，專注於天然物及生物化學的相關研究，不斷致力於新藥與檢驗試劑的開發，以及健康產品的研發，並提供各種專業生物技術服務，例如蛋白質分離、純化和鑑定技術。數年來，浩峰生技以紮實的生物有機及生物化學研發陣容為基礎，在新藥先期研究與天然物的功效研究，成果卓著。未來更以癌症的早期篩檢、免疫療法、以及生物疫苗的開發作為長期計畫目標，配合天然物的研究成果，輔助癌症患者，提高治療效果，提升生活品質，逐步實現造福人類健康的願景。 ALPS Biotech is a biotechnology company with the development of new drugs as its primary goal. It focuses on the research of natural materials and biochemistry. Besides, it is constantly developing new drugs and testing reagents, as well as research and development of health products, and providing various professional biotechnology. Services such as protein separation, purification and identification techniques. Over the years, ALPS Biotech has been based on a solid lineup of bio-organic and biochemical research and development, and it has made outstanding achievements in the research of new drugs and the efficacy of natural materials. In the future, we will use early screening of cancer, immuno-therapy as well as development of biological vaccines as long-term goals and cooperate with the research results of natural materials to assist cancer patients, improve treatment effects, improve quality of life, and gradually realize the vision of benefiting human health.

國璽幹細胞應用技術股份有限公司
Gwo Xi Stem Cell Applied Technology Co.,Ltd.

Tel:	+886-3-658-5959 #341
Website:	http://www.gwoxi.com.tw
Room No.	C523
Business/ Company Profile	國璽幹細胞 (6704) 成立於2004年，是以幹細胞技術為平台的生技新藥公司，目的為將幹細胞技術應用於再生醫學與保健醫學以開發創新的保健食品、檢測服務與新藥產品，已建立「醫藥級脂肪幹細胞製劑生產技術平台」、「臨床細胞製劑品質檢測服務」、「醫藥級幹細胞儲存服務」及多項幹細胞新藥進入人體臨床試驗，包含：GXHPC1、GXNPC1和GXCPC1。期許以幹細胞術開創全方位的價值，以維持幹細胞健康和滿足未滿足醫療需求之疾病。 GWOXI was established in 2004 as a biotech new drug company based on stem cell technology. Apply stem cell technology to regenerative medicine and health care to develop innovative health foods, testing service and new drug products. We have been established the production technology platform of pharmaceutical-grade adipose-derived stem cell products, quality testing serves of clinical cellular products, pharmaceutical-grade stem cell storage service and a number of stem cell drug. For instance, GXHPC1, GXNPC1 and GXCPC1 are ongoing clinical trial in Taiwan. We are committed to continuing to develop stem cell therapy technologies and capabilities that have broad potential of commercial applications and meet the unmet medical needs.

BIO PREVENTIVE MEDICINE

新穎生醫股份有限公司
Bio Preventive Medicine Corp.

Tel:	+886-963-072257
Website:	http://www.bpmbiotech.com
Room No.	C424
Business/ Company Profile	新穎生醫為世界級臨床階段的生物技術公司，專注於以新穎生物標記為基礎的檢測產品開發，致力於慢性疾病與癌症早期檢測與預防。擁有多項全球腎病生物標記相關專利，為腎病生物標記領域的領導公司。日前已推出糖尿病腎病變檢測技術DNlite，此技術為非侵入式尿液檢測產品。可用於早期篩檢糖尿病腎病變及其病程監控。此項技術，除了已透過實驗室檢測服務對國際大藥廠提供臨床試驗服務外，體外診斷試劑產品(DNlite-IVD103)預計於今年秋天取得CE mark，正積極尋求國際商業合作夥伴。 Bio Preventive Medicine Corp. (BPM) is a clinical-staged biotech company, we translate clinically validated and IP-protected biomarkers into diagnostic solutions of unmet clinical needs. Our focus disease area includes diabetic kidney disease (DKD) and heart complications (CVD), renal injury, and oncology. DNlite, a series of non-invasive urinary test for predicting/monitoring DKD progression, has been proven to show more sensitive than current renal standards, UACR and eGFR. As an ISO17025 and ISO13485 accredited company, BPM delivers DNlite through providing lab services and IVD kits. DNlite-IVD103 is a novel ELISA test for precision management of DKD in type 2 diabetes (T2DM). It can be used as risk assessment for predicting renal function loss in early DKD of T2DM patients, and enrichment strategy in DKD clinical trials. CE mark is expected in Q3, 2019, and BPM is currently looking for international partnership of commercialization of DNlite-IVD103.

PharmaEssentia

藥華醫藥股份有限公司
Pharmaessentia Corp.

Tel: +886-2-2655-7688

Website: http://www.pharmaessentia.com/tw

Room No. C822, C823, C824, C814

Business/ Company Profile

藥華醫藥(股票代號6446) 於2003年10月成立。公司以原創性長效型蛋白質藥物研發PEG技術平台及高難度小分子合成藥物技術等為基礎，製造出更優質的一系列突破性新藥產品，幫助病患對抗血液腫瘤、慢性肝炎及某些嚴重的癌症。公司以台灣作為全球生產基地，從實驗室到藥廠均符合歐盟EMA GMP標準，落實台灣製造、銷售世界的願景。而公司治療真性紅血球增生症(PV)新藥 Ropeginterferon alfa-2b (商品名Besremi®) 於2019年2月取得歐洲藥物管理局(EMA)上市許可，創下台灣首張EMA核准的蛋白質新藥紀錄。

PharmaEssentia Corporation (Taipei Exchange 6446) was founded in 2003 by a group of high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. The company is committed to the improvement of health and quality of life for patients suffering from these diseases. PharmaEssentia's world-class PIC/S cGMP biologics facility in Taichung was certified by the EMA in January 2018 and by the Taiwan Food and Drug Administration (TFDA) in December 2017. The Taichung plant is also designed and operated to be compliant with all US FDA requirements. And in February 2019, the Marketing Authorization for Ropeginterferon alfa-2b (Besremi®) for the treatment of Polycythemia Vera (PV) was granted by EMA.